Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts.
Spruce Biosciences Inc. (SPRB)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ikarian Capital Neil Shahrestani | 121,356 | $7,930,614 | 0.64% | |
| 2. | Millennium Management Israel Englander | 111,888 | $7,311,881 | 0% | |
| 3. | Citadel Investment Group Ken Griffin | 69,999 | $4,574,435 | 0% | |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 58,600 | $3,829,510 | +2% | 0.23% |
| 5. | Alyeska Investment Group Anand Parekh | 51,671 | $3,376,700 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.91 | 256 | $4,585.16 | 1,307 | 2025-10-06 | Filing | |
| $17.91 | 256 | $4,585.16 | 1,307 | 2025-10-06 | Filing | |
| $3.17 | 630,400 | $1,998,368.00 | 1,326,305 | 2023-02-16 | Filing | |
| $3.17 | 2,208,000 | $6,999,360.00 | 6,722,336 | 2023-02-16 | Filing | |
| $15.00 | 250,000 | $3,750,000.00 | 4,989,336 | 2020-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.46 | 25 | $436.39 | 1,050 | 2025-10-06 | Filing | |
| $19.33 | 232 | $4,483.72 | 1,075 | 2025-10-06 | Filing | |
| $17.46 | 25 | $436.39 | 1,050 | 2025-10-06 | Filing | |
| $19.33 | 232 | $4,483.72 | 1,075 | 2025-10-06 | Filing | |
| $0.75 | 465,021 | $350,951.35 | 2,550,000 | 2024-03-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 48,796 | $3,188,819 | 0% | |
| 2. | 42,080 | $2,749,928 | 0.04% | |
| 3. | 38,620 | $2,523,833 | 0.02% | |
| 4. | 26,810 | $1,752,034 | 0.09% | |
| 5. | 18,337 | $1,198,323 | 0% |
News See All
13 Best Hot Stocks to Buy According to Analysts
On March 6, Dan Niles, Niles Investment Management founder, joined 'Power Lunch' on CNBC to discuss the broader market sell-off and provide a cautious outlook on the current market environment.
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the most promising micro-cap stocks according to analysts.
12 Most Promising Micro-Cap Stocks According to Analysts
On February 27, Saira Malik, Nuveen Chief Investment Officer, joined CNBC's 'Closing Bell Overtime' to talk about what to expect from markets in the year to come.
Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript
Operator: Welcome to the Spruce Biosciences Investor Call [Operator Instructions]. Please note, this conference call is being recorded.
5 Oversold Biotech Stocks To Buy Right Now
In this article, we will be taking a look at 5 oversold biotech stocks to buy right now.
Hedge Fund and Insider Trading News: Marc Lasry, Standard General, Third Point LLC, Irenic Capital Management, Millennium Management, Soroban Capital Partners, Point72 Asset Management, Vishay Precision Group Inc (VPG), Spruce Biosciences Inc (SPRB), and More
Billionaire investor Marc Lasry has reached a deal to sell his stake in the Milwaukee Bucks to Jimmy and Dee Haslam, owners of the National Football League’s Cleveland Browns, according to a person ...
Spruce Biosciences, Inc. (SPRB): Are Hedge Funds Right About This Stock?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
5 Best Healthcare Stocks Under $20 According to Michael Castor's Sio Capital
In this article, we discuss the 5 best healthcare stocks under $20 according to Michael Castor's Sio Capital.
Hedge Fund Resource Center